ISIS up +3.47% percent Today $ISIS High is at 53.12 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 11:26 AM

ISIS up +3.47% percent Today $ISIS High is at 53.12 and the Low 51.50 with current volume of 821,968.

Recent News posted below.

Isis Pharmaceuticals ISIS other info.
http://investorshangout.com/Isis-Pharmaceuticals-ISIS-54504/

ISIS Isis Pharmaceuticals Recent Headline News

Cramer's Lightning Round - VeriFone Is Going To Have A Big Year (11/12/14)
SA Editor Miriam Metzinger - Seeking Alpha - 2 hrs 20 mins ago
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday November 12. Bullish Calls: VeriFone (NYSE: PAY ): "I like it. It is integral to Apple Pay. It is going to have a big year." ...
BTU: 11.14 (-0.46), ISIS: 51.70 (+0.62), FRT: 132.63 (+1.16), PAY: 36.71 (-0.28)

'Mad Money' Lightning Round: VeriFone Is Integral to ApplePlay
at The Street - Thu Nov 13, 5:00AM CST
Cramer says Hertz is very cheap but wants to see how their accounting problems play out.
DDR: 18.27 (+0.05), BTU: 11.14 (-0.46), HTZ: 21.88 (-0.22), ISIS: 51.70 (+0.62), ISBC: 10.79 (-0.08), FRT: 132.63 (+1.16), BAC: 17.21 (-0.08), PAY: 36.71 (-0.28)

AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
PR Newswire - Thu Nov 13, 2:01AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and AstraZeneca today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively. The agreement builds on an existing collaboration between AstraZeneca and Isis Pharmaceuticals, a leader in the field of antisense, and supports AstraZeneca's research and development capabilities in the area of antisense oligonucleotide-based therapeutics and RNA biology. Initial project areas will be oncology and cardiovascular and metabolic diseases (CVMD).
ISIS: 51.70 (+0.62)

Jim Cramer's 'Mad Money' Recap: Pining for Quiet Stock That Climbs
at The Street - Wed Nov 12, 7:57PM CST
While the bulls and bears battle it out over high-flying stocks like Alibaba and Twitter, Cramer said he'd rather just own Apple because it doesn't make waves, it makes money.
HTZ: 21.88 (-0.22), PNRA: 171.08 (+1.25), FB: 74.06 (-0.66), TCS: 22.42 (-0.23), BAC: 17.21 (-0.08), FRT: 132.63 (+1.16), YHOO: 50.06 (-0.54), DDR: 18.27 (+0.05), BTU: 11.14 (-0.46), SAVE: 78.62 (+0.26), ISIS: 51.70 (+0.62), CMG: 666.18 (+1.93), AAL: 44.05 (+0.62), ISBC: 10.79 (-0.08), PAY: 36.71 (-0.28), TWTR: 41.88 (-0.66), DOW: 50.39 (+0.49), BABA: 116.60 (-1.60)

Critical Alerts For Twitter, Isis Pharmaceuticals, TrueCar and Myriad Genetics Released By InvestorsObserver
PR Newswire - Wed Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for TWTR, ISIS, TRUE and MYGN.
MYGN: 33.25 (+0.26), ISIS: 51.70 (+0.62), TRUE: 17.19 (-0.24), TWTR: 41.88 (-0.66)

Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
PR Newswire - Wed Nov 12, 6:00AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the pricing of its offering of $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"

in a private placement. Isis also granted the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $75.0 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any. The sale of the Convertible Notes is expected to close on November 17, 2014, subject to customary closing conditions.
ISIS: 51.70 (+0.62)

Cramer's Mad Money - The Hottest Stock You've Never Heard Of (11/11/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Nov 12, 4:20AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Tuesday November 11. CEO Interview: Bill Tauscher, Blackhawk (NASDAQ: HAWK ). Other stocks mentioned: Safeway (NYSE: SWY ) Blackhawk ( HAWK ) is a leading global...
WFM: 46.56 (-0.92), DHI: 24.35 (+0.34), AMZN: 314.37 (+2.86), TSLA: 252.44 (+3.34), KR: 58.32 (-0.06), SWY: 34.89 (+0.01), CLX: 101.95 (+0.43), XOM: 94.58 (-0.80), FCAU: 12.27 (+0.60), INO: 11.00 (-0.10), WHR: 176.34 (+1.13), T: 35.80 (+0.40), ISIS: 51.70 (+0.62), VALE: 8.80 (-0.02), EOG: 95.76 (-1.80), HAWK: 37.41 (+0.21), SHW: 239.57 (+1.47), VZ: 51.05 (+0.23), TOL: 33.77 (+0.26), REGN: 397.94 (-3.17), KELYA: 15.44 (-0.20), BABA: 116.60 (-1.60)

Jim Cramer's 'Mad Money' Recap: Pile Into Housing, Biotech and Pop Cult Names
at The Street - Tue Nov 11, 7:59PM CST
Cramer says record-low interest rates seem to have finally paid off for the home builders. That means good things for the folks who make interior items, too.
DHI: 24.35 (+0.34), TSLA: 252.44 (+3.34), AMZN: 314.37 (+2.86), CY: 10.03 (-0.11), XOM: 94.58 (-0.80), KEX: 105.87 (-0.38), LRN: 12.65 (-0.16), BWLD: 164.24 (+1.24), ADBE: 71.68 (+0.27), GTLS: 44.34 (-1.91), TWX: 79.20 (+1.52), WHR: 176.34 (+1.13), T: 35.80 (+0.40), LYB: 88.13 (-0.46), ISIS: 51.70 (+0.62), CMG: 666.18 (+1.93), EOG: 95.76 (-1.80), HAWK: 37.41 (+0.21), SHW: 239.57 (+1.47), VZ: 51.05 (+0.23), DOW: 50.39 (+0.49), REGN: 397.94 (-3.17), KELYA: 15.44 (-0.20), CBS: 52.37 (+0.80)

Isis Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 8.81%
Comtex SmarTrend(R) - Tue Nov 11, 3:42PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $48.10 to a high of $52.24. Yesterday, the shares gained 8.8%, which took the trading range above the 3-day high of $47.25 on volume of 10.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 51.70 (+0.62)

One Reason Isis Pharmaceuticals (ISIS) Stock Is Gaining Today
at The Street - Tue Nov 11, 10:24AM CST
Isis Pharmaceuticals (ISIS) stock is up after the company announced it will offer $425 million in convertible senior notes.
ISIS: 51.70 (+0.62)

Isis Pharmaceuticals to launch USD425m convertible senior notes in private placement
M2 - Tue Nov 11, 6:57AM CST
Antisense drugs company Isis Pharmaceuticals (NasdaqGS:ISIS) said on Monday that it plans to offer USD425.0m aggregate principal amount of convertible senior notes due 2021 in a private placement.
ISIS: 51.70 (+0.62)

Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
PR Newswire - Mon Nov 10, 3:03PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it intends to offer, subject to market and other considerations, $425.0 million aggregate principal amount of Convertible Senior Notes due 2021 (the "Convertible Notes"

in a private placement. Isis also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $63.75 million aggregate principal amount of the Convertible Notes, solely to cover over-allotments, if any.
ISIS: 51.70 (+0.62)

ISIS Pharmaceuticals' (ISIS) CEO Stan Crooke on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 5:52PM CST

ISIS: 51.70 (+0.62)

34.6% Return Seen to Date on SmarTrend Isis Pharmaceuticals Call (ISIS)
Comtex SmarTrend(R) - Fri Nov 07, 4:40PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 3 months, Isis Pharmaceuticals has returned 34.61% as of today's recent price of $44.59.
ISIS: 51.70 (+0.62)

Look for Shares of Isis Pharmaceuticals to Potentially Rebound after Yesterday's 1.46% Sell Off
Comtex SmarTrend(R) - Fri Nov 07, 4:09PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $42.06 to a high of $44.93. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $43.87 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ISIS: 51.70 (+0.62)

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 318.96 (-2.06), ALNY: 101.91 (+2.06), ISIS: 51.70 (+0.62), OGXI: 2.16 (-0.02), TEVA: 57.93 (-0.51), RGLS: 18.60 (-1.02), GSK: 45.84 (+0.22), SNY: 46.75 (+0.19)

Isis ups revenues 87% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:53AM CST

ISIS: 51.70 (+0.62)

Isis beats 3Q profit forecasts
Automated Insights - Fri Nov 07, 7:48AM CST
CARLSBAD, Calif. (AP) _ Isis Pharmaceuticals Inc. (ISIS) on Friday reported a third-quarter loss of $26.7 million.
ISIS: 51.70 (+0.62)

Isis Pharmaceuticals misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:33AM CST

ISIS: 51.70 (+0.62)

Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
PR Newswire - Fri Nov 07, 7:30AM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today reported a pro forma net operating loss (NOL) of $13.4 million and $34.9 million for the three and nine months ended September 30, 2014, respectively, compared to an NOL of $22.7 million and $23.5 million for the same periods in 2013. Isis' revenue increased by more than 20% during the first nine months of 2014 compared to 2013 primarily due to the successes of its partnered programs as they advanced through research and development. In addition to the increase in revenue, Isis had a planned increase in operating expenses primarily associated with its late-stage clinical programs. On a GAAP basis, Isis reported a loss from operations of $21.5 million and $57.8 million for the three and nine months ended September 30, 2014, respectively, compared to a loss from operations of $25.5 million and $31.8 million for the three and nine months ended September 30, 2013. Isis ended the third quarter with $592 million in cash, compared to $657 million at December 31, 2013.
ISIS: 51.70 (+0.62)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rodeo Dental Gears Up for National Growth Surge

Rodeo Dental's Leadership Shuffle When you're talking about upping the ante in the dental world, you can't ignore the recent shake-up at Rodeo Dental & Orthodontics. They've decided to retool their corner office lineup, and this is where the folks in suits meet the folks with the steady hands in teeth. Co-Founder Dr. Saam Zarrabi is stepping into an Executive Chairman...

Graphic Packaging Names Berardinelli as HR Executive

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

CAPR Faces Lawsuit and FDA Delay: Investor Alert

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Doug Larson Takes Helm at Integra Pool Covers

A Seasoned Pro Joins Integra Pool Covers Change is afoot over at Explore Industries. They just tapped Doug Larson to be the General Manager for their Integra Pool Covers division. Now, I've seen plenty of hiring announcements in my day, but this has got an interesting ring to it. With Doug on this ship, it's like bringing a wolf back to the wild. Larson's no stranger to...

Yardi Virtuoso AI to Shine at CAIC 2026 Toronto

The Scene in Toronto: Yardi's Big AI Showcase There's no denying it—Artificial Intelligence has muscled its way into practically every corner of the business world, and now it's making waves in real estate. Yardi, a familiar name in real estate tech circles, is gearing up to flaunt its Yardi Virtuoso Enterprise at the Canadian Apartment Investment Conference (CAIC) in...

USF Law Innovators: Leading AI Integration in Academics

Revolutionizing Legal Academia with AI If there's one thing that's caught my eye in the realm of education, it's how some folks over at the University of San Francisco School of Law are shaking things up. These legal eagles aren't messing around with the usual, archaic ways of teaching the law. Nope, they've dove headfirst into the future by hooking their curriculum to...

McCann Systems Scores Big with Dual AV Awards Wins

Piling Up the Accolades: McCann Systems Does It Again You know, getting industry awards can sometimes feel like counting beans, but when a company's snagging them year after year, that’s worth noting. McCann Systems is strutting its stuff with two Commercial Integrator Awards in 2026, cementing their reputation not just here in New Jersey, but across the AV industry....

Safety and Wellbeing as Key Business Strategy Focus

Revolutionizing Safety in the Workplace Cracking the typical mindset of treating employee safety as a checkbox item, Debra Wein, CEO and Founder of Wellness Workdays, is set to shake up the NSC Safety Congress & Expo. Her upcoming session, titled "Transforming Safety and Wellbeing into a Competitive Business Advantage," isn't just a run-of-the-mill talk. It's a call to...

Alcatraz AI: A Silent Titan in Data Center Security

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...

APX Bridges Crypto & Traditional Finance With New Credit Line

The Future of Financial Bridging Now here's a scenario that might perk your ears up if you've ever toyed with digital assets: APX Lending is stepping up its game, bringing a regulated five-year revolving line of credit backed by Bitcoin and Ethereum to the world stage. It's like blending your grandma's tried-and-true savings approach with the whiz-bang allure of crypto. A...